<DOC>
	<DOCNO>NCT00849654</DOCNO>
	<brief_summary>The purpose study establish safety optimal dose orally administer PCI-32765 patient recurrent B cell lymphoma .</brief_summary>
	<brief_title>Study Safety Tolerability PCI-32765 Patients With Recurrent B Cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Leukemia , B-Cell</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<criteria>Women men ≥ 18 year age . There experience drug pediatric population . Body weight ≥ 40 kg . Recurrent surface immunoglobulin positive B cell nonHodgkin 's lymphoma ( NHL ) accord WHO classification , include small lymphocytic lymphoma/ chronic lymphocytic leukemia ( SLL/CLL ) lymphoplasmacytic lymphoma , include Waldenström 's Macroglobulinemia ( WM ) , preidentified DLBCL ABC subtype oFor DLBCLABC cohort , document , activate Bcell subtype either immunohistochemistry tissue microarray analysis . Measurable disease ( NHL , bidimensional disease ≥ 2 cm diameter least one dimension , CLL ≥ 5000 leukemia cells/mm3 , WM presence immunoglobulin M paraprotein minimum IgM level ≥ 1000 mg/dL infiltration bone marrow lymphoplasmacytic cell ) , preidentified DLBCL ABC subtype immunohistochemistry ( IHC ) . Have fail ≥ 1 previous treatment lymphoma standard therapy available . Patients diffuse large B cell lymphoma must fail , refuse ineligible autologous stem cell transplant . ECOG performance status ≤ 1 . Ability swallow oral capsule without difficulty . Willing able sign write informed consent . More four prior systemic therapy ( count maintenance rituximab ) , except CLL patient . Salvage therapy/conditioning regimen lead autologous bone marrow transplantation consider one regimen ( This inclusion criterion apply DLBCLABC cohort ) . Prior allogeneic bone marrow transplant . Immunotherapy , chemotherapy , radiotherapy experimental therapy within 4 week first day study drug dose . Major surgery within 4 week first day study drug dose . CNS involvement lymphoma . Active opportunistic infection treatment opportunistic infection within 4 week first day study drug dose . History malabsorption . Laboratory abnormality : Creatinine &gt; 1.5 × institutional upper limit normal ( ULN ) Total bilirubin &gt; 1.5 x institutional ULN ( unless elevate document Gilbert 's syndrome ) AST ALT &gt; 2.5 × institutional ULN Platelet count &lt; 75,000/µL ( unless patient CLL bonemarrow involvement , provide transfusiondependent ) Absolute neutrophil count ( ANC ) &lt; 1500/µL ( unless patient CLL bonemarrow involvement ) Hgb &lt; 8.0 g/dL Uncontrolled illness include limited : ongoing active infection , symptomatic congestive heart failure ( New York Heart Association Class III IV heart failure ) , unstable angina pectoris , cardiac arrhythmia , psychiatric illness would limit compliance study requirement . Risk factor , use medication know prolong QTc interval may associate Torsades de Pointes within 7 day treatment start . QTc prolongation ( define QTc &gt; 450 msec ) significant ECG abnormality include 2nd degree AV block type II , 3rd degree AV block , bradycardia ( ventricular rate le 50 beats/min ) . If screen ECG QTc &gt; 450 msec , ECG submit centralize , cardiologic evaluation . History myocardial infarction , acute coronary syndrome ( include unstable angina ) , coronary angioplasty and/or stenting within past 6 month . Known HIV infection . Hepatitis B sAg Hepatitis C positive . Other medical psychiatric illness organ dysfunction , opinion investigator , would either compromise patient 's safety interfere evaluation safety study agent . Pregnant lactate woman ( female patient childbearing potential must negative serum pregnancy test within 14 day first day drug dosing , , positive , pregnancy rule ultrasound ) . Women childbearing potential sexually active men , unwilling use adequate contraceptive protection course study . History prior cancer &lt; 2 year ago , except basal cell squamous cell carcinoma skin , cervical cancer situ situ carcinoma .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>PCI-32765</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Lymphoma , Non-Hodgkin</keyword>
	<keyword>Lymphoma , B-Cell</keyword>
	<keyword>Burkitt Lymphoma</keyword>
	<keyword>Lymphoma , B-Cell , Marginal Zone</keyword>
	<keyword>Lymphoma , B-Cell , Diffuse</keyword>
	<keyword>Lymphoma , Follicular</keyword>
	<keyword>Lymphoma , Mantle Cell</keyword>
	<keyword>Leukemia , Lymphoid</keyword>
	<keyword>Leukemia , B-Cell</keyword>
	<keyword>Waldenstrom macroglobulinemia</keyword>
	<keyword>Bruton 's Tyrosine Kinase</keyword>
</DOC>